These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 27211079

  • 1. Preventing cervical cancer and genital warts - How much protection is enough for HPV vaccines?
    Stanley M.
    J Infect; 2016 Jul 05; 72 Suppl():S23-8. PubMed ID: 27211079
    [Abstract] [Full Text] [Related]

  • 2. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER, Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 2007 Mar 23; 56(RR-2):1-24. PubMed ID: 17380109
    [Abstract] [Full Text] [Related]

  • 3. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL, Joura EA.
    BioDrugs; 2011 Oct 01; 25(5):339-43. PubMed ID: 21942919
    [Abstract] [Full Text] [Related]

  • 4. HPV vaccines to prevent cervical cancer and genital warts: an update.
    Dochez C, Bogers JJ, Verhelst R, Rees H.
    Vaccine; 2014 Mar 20; 32(14):1595-601. PubMed ID: 24606637
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E, López-Lacort M, Navarro-Illana P, Vilata JJ, Diez-Domingo J.
    Vaccine; 2017 Jun 05; 35(25):3342-3346. PubMed ID: 28499554
    [Abstract] [Full Text] [Related]

  • 6. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
    McCormack PL, Joura EA.
    Drugs; 2010 Dec 24; 70(18):2449-74. PubMed ID: 21142263
    [Abstract] [Full Text] [Related]

  • 7. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
    Khaliq SA, Shyum Naqvi SB, Fatima A.
    Pak J Pharm Sci; 2012 Oct 24; 25(4):763-72. PubMed ID: 23009992
    [Abstract] [Full Text] [Related]

  • 8. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience.
    Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, Saah AJ, Drury R, Das R, Velicer C.
    Clin Infect Dis; 2016 Aug 15; 63(4):519-27. PubMed ID: 27230391
    [Abstract] [Full Text] [Related]

  • 9. Developing an HPV vaccine to prevent cervical cancer and genital warts.
    Bryan JT.
    Vaccine; 2007 Apr 20; 25(16):3001-6. PubMed ID: 17289220
    [Abstract] [Full Text] [Related]

  • 10. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C, Roden RBS, Kirnbauer R.
    Virus Res; 2017 Mar 02; 231():166-175. PubMed ID: 27889616
    [Abstract] [Full Text] [Related]

  • 11. Population impact of HPV vaccines: summary of early evidence.
    Hariri S, Markowitz LE, Dunne EF, Unger ER.
    J Adolesc Health; 2013 Dec 02; 53(6):679-82. PubMed ID: 24263069
    [Abstract] [Full Text] [Related]

  • 12. Epidemiology and natural history of genital human papillomavirus infection.
    Weaver BA.
    J Am Osteopath Assoc; 2006 Mar 02; 106(3 Suppl 1):S2-8. PubMed ID: 16729554
    [Abstract] [Full Text] [Related]

  • 13. Using the new HPV vaccines in clinical practice.
    Widdice LE, Kahn JA.
    Cleve Clin J Med; 2006 Oct 02; 73(10):929-35. PubMed ID: 17044318
    [Abstract] [Full Text] [Related]

  • 14. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.
    McCormack PL.
    Drugs; 2014 Jul 02; 74(11):1253-83. PubMed ID: 25022951
    [Abstract] [Full Text] [Related]

  • 15. A prophylactic quadrivalent vaccine for the prevention of infection and disease related to HPV-6, -11, -16 and -18.
    Goldstone SE, Vuocolo S.
    Expert Rev Vaccines; 2012 Apr 02; 11(4):395-406. PubMed ID: 22551023
    [Abstract] [Full Text] [Related]

  • 16. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.
    Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.
    J Natl Cancer Inst; 2012 Nov 21; 104(22):1712-23. PubMed ID: 23104323
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Human papillomavirus vaccines and vaccine implementation.
    de Sanjosé S, Alemany L, Castellsagué X, Bosch FX.
    Womens Health (Lond); 2008 Nov 21; 4(6):595-604. PubMed ID: 19072462
    [Abstract] [Full Text] [Related]

  • 20. What can surveillance of genital warts tell us?
    Fairley CK, Donovan B.
    Sex Health; 2010 Sep 21; 7(3):325-7. PubMed ID: 20719222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.